Showing posts with label chronic lymphocytic leukemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL). Show all posts
Showing posts with label chronic lymphocytic leukemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL). Show all posts
Tuesday, September 20, 2016

Ibrutinib: Indication of added benefit in one of three therapeutic indications...

›
In continuation of my update on Ibrutinib Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the tre...